A Phase 2 interventional study of rF1V-1018 and rF1V vaccine in Plague, Pneumonic, Plague and Vaccine-Preventable Diseases, sponsored by Dynavax Technologies Corporation. Completed at 6 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-29.
Sponsored by Dynavax Technologies Corporation (part of Sanofi) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Vaccine-Preventable Diseases with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Vaccine-Preventable Diseases · United States.
Among the 16 studies in Vaccine-Preventable Diseases with a site in United States, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2022, is the only one in phase 2, and was the 7th registered.
53 studies on the registry are indexed under Vaccine-Preventable Diseases; 12 are open to participants now.
Browse Vaccine-Preventable Diseases studies →1 of the 16 studies in Vaccine-Preventable Diseases with a site in United States is open now. Recruiting first, the newest first:
Michigan State University · Sites in United States
Ages 11–14 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Vaccine-Preventable Diseases studies recruiting now, 2 set no upper age limit and 6 stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2022.
This study's enrollment of 200 is close to the median of 190 across 42 interventional studies indexed under Vaccine-Preventable Diseases.
Median enrollment 133 across the 15 interventional studies, 71 across the 1 observational. Of the 14 that completed or were terminated, 6 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under Dynavax Technologies Corporation, one of the names counted as Sanofi. Under that name alone:
Dynavax Technologies Corporation is the lead sponsor of 25 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 6 (86%) have results posted.
Sanofi has 3 studies filed under Vaccine-Preventable Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Vaccine-Preventable Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05984849Michigan State UniversityPlaying Game to Learn About Children's Vaccine Project | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Vaccine-Preventable Diseases with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine with CpG 1018® Adjuvant Compared with rF1V Vaccine in Adults 18 to 55 Years of Age
Phase 2, randomized, active-controlled, observer-blind, multicenter trial of the immunogenicity, safety, and tolerability of rF1V vaccine with CpG 1018® adjuvant (rF1V-1018) compared with rF1V vaccine alone in adults. Approximately two hundred healthy adults 18 to 55 years of age will be enrolled to compare a two-dose regimen of rF1V-1018 with a three-dose regimen of rF1V vaccine alone. The study will be conducted in 2 parts (Part 1 and Part 2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pre-existing stable medical condition means a subject who: has full capacity of daily activity and no major medication modification within 3 months prior to Day 1; has not undergone surgical or minimally-invasive intervention or had any hospitalization/emergency room visit for the specific medical condition.
If female of and heterosexually active, has practiced adequate for 28 days prior to vaccination and has negative pregnancy tests just prior to vaccination and has agreed to continue adequate contraception until 28 days after last study injection. Adequate contraception is defined as a contraceptive method with a failure rate of \< 1% per year when used consistently and correctly and, when applicable, in accordance with the product label. Examples include the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Co-administration of rF1V vaccine and CpG 1018® adjuvant administered as 2 injections
Biological: rF1V-1018
Bedside mix of rF1V vaccine and CpG 1018® adjuvant administered administered as 2 injections
Biological: rF1V-1018
rF1V vaccine administered as 3 injections
Biological: rF1V vaccine
rF1V vaccine and CpG 1018® adjuvant
rF1V vaccine
Rates of Reactogenicity and Safety
Rates of solicited local and systemic post-injection reactions, and AEs, severe AEs, SAEs, AESIs, and deaths
Time frame: Day 1 to Week 56
| Milestone | rF1V-1018 Co-Administered | rF1V-1018 Bedside Mix | rF1V Vaccine Only |
|---|---|---|---|
| Started | 21 | 90 | 89 |
| Completed | 18 | 81 | 77 |
| Not completed | 3 | 9 | 12 |
Rates of solicited local and systemic post-injection reactions, and AEs, severe AEs, SAEs, AESIs, and deaths
| Participants | rF1V-1018 Co-Administered | rF1V-1018 Bedside Mix | rF1V Vaccine Only |
|---|---|---|---|
| Local Reactions | 16 | 67 | 57 |
| Severe Local Reactions | 0 | 0 | 2 |
| Systemic Reactions | 13 | 60 | 42 |
| Severe Systemic Reactions | 0 | 2 | 0 |
| At least 1 Unsolicited AE | 7 | 27 | 28 |
| Severe (Grade 3 or 4) AEs | 2 | 1 | 5 |
| SAEs | 1 | 0 | 3 |
| AESIs | 1 | 0 | 1 |
| Deaths | 0 | 0 | 1 |
Collected over Participants were followed for post-injection local and systemic reaction for 7 days post each injection and for AEs, SAEs, and imAESIs through Day 393 (Week 56).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rF1V-1018 Co-Administered | 0/21 (0%) | 1/21 (4.8%) | 18/21 (85.7%) |
| rF1V-1018 Bedside Mix | 0/90 (0%) | 0/90 (0%) | 77/90 (85.6%) |
| rF1V Vaccine Only | 1/89 (1.1%) | 3/89 (3.4%) | 69/89 (77.5%) |
| Event | rF1V-1018 Co-Administered | rF1V-1018 Bedside Mix | rF1V Vaccine Only |
|---|---|---|---|
| Cor Pulmonale AcuteCardiac disorders | 1/21 | 0/90 | 0/89 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/21 | 0/90 | 0/89 |
| Deep Vein ThrombosisVascular disorders | 1/21 | 0/90 | 0/89 |
| Complicated AppendicitisInfections and infestations | 0/21 | 0/90 | 1/89 |
| AppendicitisInfections and infestations | 0/21 | 0/90 | 1/89 |
| Toxicity to Various AgentsInjury, poisoning and procedural complications | 0/21 | 0/90 | 1/89 |
| Event | rF1V-1018 Co-Administered | rF1V-1018 Bedside Mix | rF1V Vaccine Only |
|---|---|---|---|
| Injection Site PainGeneral disorders | 16/21 | 66/90 | 56/89 |
| FatigueGeneral disorders | 10/21 | 43/90 | 30/89 |
| MyalgiaMusculoskeletal and connective tissue disorders | 9/21 | 23/90 | 22/89 |
| HeadacheNervous system disorders | 8/21 | 34/90 | 25/89 |
| DiarrhoeaGastrointestinal disorders | 7/21 | 15/90 | 12/89 |
| MalaiseGeneral disorders | 6/21 | 25/90 | 21/89 |
| NauseaGastrointestinal disorders | 4/21 | 13/90 | 12/89 |
| Injection Site PruritusGeneral disorders | 2/21 | 17/90 | 13/89 |
| ChillsGeneral disorders | 3/21 | 13/90 | 14/89 |
| UrticariaSkin and subcutaneous tissue disorders | 2/21 | 0/90 | 0/89 |
Safety analysis population: All participants who received at least 1 study injection and had any post-baseline safety data
| Age, Customized(Years) | rF1V-1018 Co-Administered | rF1V-1018 Bedside Mix | rF1V Vaccine Only | Total |
|---|---|---|---|---|
| Mean (SD) | 39.1 ± 8.17 | 40.0 ± 9.2 | 37.9 ± 9.91 | 39.0 ± 9.76 |
| Age, Customized(Participants) | rF1V-1018 Co-Administered | rF1V-1018 Bedside Mix | rF1V Vaccine Only | Total |
|---|---|---|---|---|
| 18-39 | 12 | 42 | 46 | 100 |
| 40+ | 9 | 48 | 43 | 100 |
| Sex: Female, Male(Participants) | rF1V-1018 Co-Administered | rF1V-1018 Bedside Mix | rF1V Vaccine Only | Total |
|---|---|---|---|---|
| Female | 9 | 34 | 36 | 79 |
| Male | 12 | 56 | 53 | 121 |
| Ethnicity (NIH/OMB)(Participants) | rF1V-1018 Co-Administered | rF1V-1018 Bedside Mix | rF1V Vaccine Only | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 8 | 10 | 18 |
| Not Hispanic or Latino | 21 | 77 | 77 | 175 |
| Unknown or Not Reported | 0 | 5 | 2 | 7 |
| Race/Ethnicity, Customized(Participants) | rF1V-1018 Co-Administered | rF1V-1018 Bedside Mix | rF1V Vaccine Only | Total |
|---|---|---|---|---|
| White | 14 | 62 | 62 | 138 |
| Black or African American | 4 | 19 | 20 | 43 |
| American Indian or Alaska Native | 1 | 1 | 0 | 2 |
| Asian | 1 | 2 | 2 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 2 | 3 |
| Other | 1 | 5 | 3 | 9 |
| Body mass index((kg/m^2)) | rF1V-1018 Co-Administered | rF1V-1018 Bedside Mix | rF1V Vaccine Only | Total |
|---|---|---|---|---|
| Mean | 26.5 ± 2.46 | 25.9 ± 3.04 | 25.5 ± 3.16 | 25.8 ± 3.04 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Oct 2023, 13 months.
Results were first posted in Jul 2025, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vaccine-Preventable Diseases →
Dynavax Technologies Corporation →